Walleye Capital
IRWD icon

Walleye Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Walleye Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9K Buy
+8,800
New +$36.1K ﹤0.01% 4003
2020
Q1 		– Sell
-11,200
Closed -$149K – 1292
2019
Q4 		$149K Buy
+11,200
New +$123K 0.01% 1236

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Walleye Capital's IRWD Position: Q1 2026 in Review

Walleye Capital reduced its Ironwood Pharmaceuticals (IRWD) stake by 57% in Q1 2026, selling an estimated $1.24M and leaving 225,136 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

Walleye Capital first reported a position in IRWD in Q4 2019 and has held it in 9 quarters since. The position peaked at $2.57M in Q4 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Walleye Capital held 225,136 shares of Ironwood Pharmaceuticals worth $790K as of Q1 2026.
  • Walleye Capital sold 302,800 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2291 holding.
  • Walleye Capital first reported a position in Ironwood Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
  • Walleye Capital's Ironwood Pharmaceuticals position peaked at $2.57M in Q4 2024.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.